A Biostatistics Paper Alleges Potential Harm To Patients In Two Duke Clinical Studies
...
Duke Scandal
Duke University Suspends Two Clinical Trials After Journal Paper Questions Assay Validity
...
A high-profile cancer genomics researcher at Duke University claimed in multiple grant applications that he had been a Rhodes scholar, when, in fact, the Rhodes Trust states flatly that he was not.
By Defending Potti, Duke Officials Become Target Of Charges Of Institutional Failure
...
Michigan Scientist David Beer Sought Retraction Of Potti’s NEJM Paper Over Misuse Of His Data
...
Guest Editorial: Anil Potti Hires “Online Reputation Managers” As Journals Retract His Biomarker Research
...
A Year at NCI: Harold Varmus Reflects On Provocative Questions, The Duke Scandal, Financial Disaster And Grant Review
...
Clinical Trial Participants Sue Duke University, Potti, Nevins and Others for Causing Harm
...
Duke Researchers Retract Paper from Blood; Dozens of Retractions of Potti’s Work Expected
...
Anil Potti Explains: “Coming from India, I Did Not Know This Was Not The Real Rhodes Scholarship”
...
FDA Didn’t Punish Duke for Failing To Seek Proper Regulatory Clearance for Three Trials
...
Nevins Reverses Position, Claims Potti Manipulated Data For Basis of Clinical Trials
...
Duke University would have avoided embarrassment, a misconduct investigation and a lawsuit, had its top administrators paid closer attention to a thoughtful report by a medical student who saw problems in the lab of the disgraced scientist Anil Potti.
Repeating the Third Year?
Nevins Acknowledges Gravity of the Situation
New Perspective on Nevins and Potti
In May 2008, the Blue Devils of genomic medicine were facing a mortal threat.
On Jan. 9, 2015, The Cancer Letter reported that Duke University received information in early 2008 that called into question the validity of the methodology and results published by the Anil Potti research group. Potti, along with his mentor and co-author Joseph Nevins, had galvanized the world of cancer research in 2006 and 2007 with their reports of successful gene expression tests for directing cancer therapy, the “holy grail” of cancer research. The 2008 information came in the form of a letter from a third-year medical student, Brad Perez, who was working in Potti's lab. The letter, which does not seem to have been given any credence at the time, described with precision the problems that eventually resulted in the termination of clinical trials and the subsequent retractions, beginning in 2011, of at least ten (and counting) papers from major scientific journals.
